The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Essix Biosciences Ltd
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The promoter group of Ind-Swift Laboratories, led by Essix Biosciences Ltd along with 20 individuals (PACs), has acquired 45,15,495 equity shares (5.53% of total share capital, 4.83% on diluted basis) through an allotment pursuant to the scheme of amalgamation of Ind-Swift Limited (transferor) into Ind-Swift Laboratories Limited (transferee). The allotment was made on August 25, 2025. Post-acquisition, the promoter group's combined holding stands at 3,22,34,278 shares, representing 39.50% of total share/voting capital (up from 37.72% before the acquisition). The company's equity share capital has expanded from INR 73.49 crores (7.34 crore shares) to INR 81.61 crores (8.16 crore shares) due to the issuance of new shares to effect the amalgamation. The disclosure was triggered because the acquisition exceeded the 5% reporting threshold under SEBI takeover regulations.
This is a structural consolidation rather than an open-market purchase, so there is no immediate cash impact on the stock. Promoter control has strengthened marginally (from ~37.7% to ~39.5%), but existing non-promoter shareholders have seen their proportional holding diluted by the issuance of new shares for the amalgamation. The scheme reinforces promoter commitment to the listed entity.